Effect of Benralizumab in Patients With Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Case Series
| Autor: | Elina Toskala, Mindy Rabinowitz, Prachi Patel, Kira Murphy, Stephanie Bork, Alan Gandler, Tawfiq Khoury, Pamela Monostra, Chandala Chitguppi, Jessica Most, Marc Rosen, Gurston Nyquist |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Chronic rhinosinusitis Eosinophilic asthma Antibodies Monoclonal Humanized 03 medical and health sciences chemistry.chemical_compound Nasal Polyps 0302 clinical medicine Humans Immunology and Allergy Medicine Nasal polyps In patient 030223 otorhinolaryngology Retrospective Studies business.industry General Medicine medicine.disease Benralizumab Dermatology Asthma 030228 respiratory system Otorhinolaryngology chemistry Quality of Life business |
| Zdroj: | American Journal of Rhinology & Allergy. 35:559-567 |
| ISSN: | 1945-8932 1945-8924 |
| Popis: | Objective To analyze the effect of benralizumab in severe eosinophilic asthma (SA) and chronic rhinosinusitis with polyps (CRSwP). Methods Retrospective review of patients with both SA and CRSwP that were treated with benralizumab. Asthma controlled test (ACT), pulmonary function metrics (FEV1), Meltzer endoscopic polyp scores, SNOT-22 scores, were collected before and after at least 4 months of benralizumab therapy. Results 23 patients were included. The mean age at the time of enrollment into benralizumab therapy was 50.47 ± 17.3 years and majority (65.2%, n = 15) were males. Pulmonary Effects: In comparison to baseline ACT, scores at four months showed significant improvement (p = 0.03). In those with pre and post spirometry measurements, mean FEV1 showed significant increase following benralizumab therapy (p = 0.04) with a mean increase of 547 mL ± 597 mL following therapy. Sinonasal Effects: 78.5% of subjects on benralizumab had a significant improvement in sinonasal symptoms (p = 0.009) based on their SNOT-22 scores. Additionally, there was an improvement in endoscopic polyp scores, although not statistically significant, following benralizumab therapy (p = 0.2) with 54.5% patients showing improvement. Conclusion Usage of benralizumab in patients with SA and CRSwNP can lead to significantly improved asthma control, lung function, and sinonasal quality of life. Additionally, in this patient population, there was a subset of patients that showed a significant reduction in polyp burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|